
Drugmakers may have new, very expensive obesity-control drugs in the pipeline that will work better than the ones available today.
Executives from one biotech firm, Viking Therapeutics, told securities analysts during a conference call Wednesday that early trials show that the injected version of its VK2735 drug helped study obese participants lose up to about 13% of their weight after just 13 weeks, with no serious side effects and no sign that weight loss was slowing down at the end of that period.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more information visit Asset & Logo Licensing.